Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Messing

Showing results (41-50 of 199) with videos related to

Pageof 20
Sort By:
The Urologic Clinics of North America|December 19, 2003
Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapyEdward M Messing, Ian Thompson
Bladder Cancer (Amsterdam, Netherlands)|January 22, 2026
Neoadjuvant chemotherapy for high-risk upper tract urothelial cancerKamil Malshy, Edward M Messing
BMC Urology|September 12, 2009
Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuriaDeep Trivedi, Edward M Messing
Cancer|October 26, 2012
Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over timeEmil Scosyrev, Edward M Messing
World Journal of Urology|November 28, 2007
Long-term outcome of home dipstick testing for hematuriaRalph Madeb, Edward M Messing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2025
Single-Arm Pivotal Studies in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder CancerJathin Bandari, Edward M Messing
Current Urology Reports|May 27, 2004
Early versus late hormonal therapy for prostate cancerHiroshi Miyamoto, Edward M Messing
BJU International|August 23, 2011
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?Emil Scosyrev, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|May 9, 2025
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancerEdward M Messing, Kamil Malshy
Bladder Cancer (Amsterdam, Netherlands)|November 10, 2025
Can urinary tumor DNA be used to assess the risk of recurrence in patients with non-muscle invasive bladder cancer?Kamil Malshy, Edward M Messing
Pageof 20

Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
The Urologic Clinics of North America|December 19, 2003
Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapyEdward M Messing, Ian Thompson
Bladder Cancer (Amsterdam, Netherlands)|January 22, 2026
Neoadjuvant chemotherapy for high-risk upper tract urothelial cancerKamil Malshy, Edward M Messing
BMC Urology|September 12, 2009
Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuriaDeep Trivedi, Edward M Messing
Cancer|October 26, 2012
Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over timeEmil Scosyrev, Edward M Messing
World Journal of Urology|November 28, 2007
Long-term outcome of home dipstick testing for hematuriaRalph Madeb, Edward M Messing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2025
Single-Arm Pivotal Studies in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder CancerJathin Bandari, Edward M Messing
Current Urology Reports|May 27, 2004
Early versus late hormonal therapy for prostate cancerHiroshi Miyamoto, Edward M Messing
BJU International|August 23, 2011
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?Emil Scosyrev, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|May 9, 2025
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancerEdward M Messing, Kamil Malshy
Bladder Cancer (Amsterdam, Netherlands)|November 10, 2025
Can urinary tumor DNA be used to assess the risk of recurrence in patients with non-muscle invasive bladder cancer?Kamil Malshy, Edward M Messing
Pageof 20